SAN DIEGO, CA / ACCESS Newswire / January 31, 2025 / Robbins LLP reminds stockholders that a class action was filed on behalf of all investors ...

If you suffered substantial losses and wish to serve as lead plaintiff of the Novo Nordisk class action lawsuit, please ...

Drug manufacturer Novo Nordisk's amycretin, an experimental weight-loss pill in clinical trials, may boast substantial weight ...

Donald Trump has on several occasions floated the idea of buying Greenland, the autonomous Danish territory. However, there is no shortage of economic leverage for Denmark to hurt the United States.

While the attention of late has been firmly focused on Novo Nordisk's obesity and diabetes business – which is also seeing heavy investment in manufacturing – the company has a longstanding ...

New data from Novo Nordisk’s phase 3 trial of an oral, high-dose formulation of semaglutide reinforces its potential as a weight-loss therapy in obesity, but Eli Lilly is in hot pursuit.

President Trump has said he plans to raise or impose new tariffs on a wide range of products, including pharmaceuticals. While Trump has openly discussed rolling out tariffs on China, Mexico and ...

Report with the AI impact on market trends - The global biotech market size is estimated to grow by USD 805.6 billion from 2025-2029, according to Technavio. The market is estimated to grow at a CAGR ...

China Universal Asset Management Co. Ltd. lessened its stake in Novo Nordisk A/S (NYSE:NVO – Free Report) by 4.8% during the 4th quarter, according to the company in its most recent filing with the ...

$ 81.33 0.23 0.28% ...